PDL restructures to recover
PDL Biopharma has restructured its board of directors and reaffirmed its strategic focus as it attempts to recover from a challenging period.
PDL Biopharma has restructured its board of directors and reaffirmed its strategic focus as it attempts to recover from a challenging period.
Agilent Technologies has licensed BIA Separations' bio-monolithic technology and intends to use it in the commercialisation of analytical high performance liquid chromatography (HPLC) bio-monolith columns.
US drug giant Pfizer hopes that its collaboration with student engineers at New Jersey's Rowan University will help lessen the environmental impact of its best selling arthritis drug Celebrex (celeboxib).
in-PharmaTechnologist.com presents its periodic round-up of personnel changes in pharmaceutical manufacturing and development.